{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T23:43:37Z","timestamp":1773791017184,"version":"3.50.1"},"reference-count":36,"publisher":"Informa UK Limited","issue":"6","funder":[{"name":"Amgen (Europe) GmbH, Zug, Switzerland"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Hematology"],"published-print":{"date-parts":[[2020,6,2]]},"DOI":"10.1080\/17474086.2020.1746639","type":"journal-article","created":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T11:45:28Z","timestamp":1586173528000},"page":"687-696","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Cost-effectiveness of once weekly carfilzomib 70 mg\/m2 plus dexamethasone in patients with relapsed and refractory multiple myeloma in the United States"],"prefix":"10.1080","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5336-261X","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"first","affiliation":[{"name":"Division of Hematology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istvan","family":"Majer","sequence":"additional","affiliation":[{"name":"Global Health Economics, Amgen (Europe) GmbH, Rotkreuz, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumeet","family":"Panjabi","sequence":"additional","affiliation":[{"name":"Global Health Economics, Amgen, South San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohan","family":"Medhekar","sequence":"additional","affiliation":[{"name":"Global Health Economics, Amgen, Thousand Oaks, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Campioni","sequence":"additional","affiliation":[{"name":"Global Health Economics, Amgen, Thousand Oaks, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"School of Medicine, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2020,4,6]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442"},{"key":"cit0002","unstructured":"American Cancer Society. Key statistics about multiple myeloma; 2018 [cited 2018 Oct 23]. Available from: https:\/\/www.cancer.org\/cancer\/multiple-myeloma\/about\/key-statistics.html"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60221-X"},{"key":"cit0004","unstructured":"American Cancer Society. Signs and symptoms of multiple myeloma; 2018 [cited 2018 Oct 23]. Available from: https:\/\/www.cancer.org\/cancer\/multiple-myeloma\/detection-diagnosis-staging\/signs-symptoms.html"},{"key":"cit0005","unstructured":"Durie BGM Concise review of the disease and treatment options. International Myeloma Foundation (2017 Edition) 2017 [cited 2017 Oct 17]. Available from: https:\/\/www.myeloma.org\/sites\/default\/files\/images\/publications\/UnderstandingPDF\/concisereview.pdf"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.4065\/79.7.867"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2013.07.007"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2012.05.003"},{"key":"cit0009","unstructured":"Amgen data on file. 2019. Calculated weighted average by line based on Amgen chart review data."},{"key":"cit0010","unstructured":"Food and Drug Administration. KYPROLIS\u00ae (carfilzomib) for injection, for intravenous use: highlights of prescribing information; 2019 [cited 2019 Jan 21]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/202714s025lbl.pdf"},{"issue":"1","key":"cit0011","first-page":"5441","volume":"130","author":"Kim C","year":"2017","journal-title":"Blood"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113414"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30354-1"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0480-2"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2017.1391088"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2016.1194278"},{"key":"cit0017","unstructured":"SEER. Surveillance, epidemiology, and end results program. Stat Fact Sheets: Myeloma; 2016 [cited 2016 Mar 28]. Available from: http:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html"},{"key":"cit0018","volume-title":"The United States of America, life tables","author":"Human Mortality Database","year":"2018"},{"key":"cit0019","unstructured":"Analysource. Wholesale acquisition cost (WAC); 2018 [cited 2018 Oct 8]. Available from: https:\/\/www.analysource.com\/"},{"key":"cit0020","unstructured":"Centers for Medicare & Medicaid Services (CMS). National physician fee schedule 2018 [cited 2018 Oct 8]. Available from: https:\/\/www.cms.gov\/apps\/physician-fee-schedule\/"},{"key":"cit0021","volume-title":"National Inpatient Sample (NIS), Agency for Healthcare Research and Quality (AHRQ). National statistics by principal diagnosis code","author":"HCUPnet","year":"2015"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12472398"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X16639900"},{"key":"cit0024","unstructured":"Latimer N NICE DSU technical support document 14: undertaking survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data 2013 [updated 2013 Mar; 2017 Jan 30]. Available from: http:\/\/nicedsu.org.uk\/wp-content\/uploads\/2016\/03\/NICE-DSU-TSD-Survival-analysis.updated-March-2013.v2.pdf"},{"issue":"8","key":"cit0025","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.ejca.2004.01.019","volume":"40","author":"van Agthoven M","year":"2004","journal-title":"Eur J Cancer"},{"key":"cit0026","unstructured":"National Institute for Health and Care Excellence. Pomalidomide for relapsed and refractory multiple myeloma previously treated with lenalidomide and bortezomib [TA338] 2015. [cited 2019 Apr 30]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta338"},{"key":"cit0027","unstructured":"National Institute for Health and Care Excellence. Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (TA510); 2018 [cited 2018 Oct 11]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta510\/"},{"key":"cit0028","volume":"4","author":"Bennison C","year":"2016","journal-title":"J Mark Access Health Policy"},{"key":"cit0029","unstructured":"Amgen data on file. Retrospective study of healthcare utilization and costs in patients with multiple myeloma using Truven MarketScan Data through December 2014; 2015."},{"key":"cit0030","unstructured":"Bureau of Labor Statistics. Consumer Price Index (CPI) for medical care services in the U.S. for all urban consumers; 2018 [cited 2018 Oct 10]. Available from: https:\/\/data.bls.gov\/timeseries\/CUSR0000SAM2"},{"key":"cit0031","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.0534"},{"key":"cit0032","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1405158"},{"key":"cit0033","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0759-6"},{"key":"cit0034","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2010.01526.x"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2011.611841"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju002"}],"container-title":["Expert Review of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474086.2020.1746639","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T12:55:31Z","timestamp":1620478531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474086.2020.1746639"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,6]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6,2]]}},"alternative-id":["10.1080\/17474086.2020.1746639"],"URL":"https:\/\/doi.org\/10.1080\/17474086.2020.1746639","relation":{},"ISSN":["1747-4086","1747-4094"],"issn-type":[{"value":"1747-4086","type":"print"},{"value":"1747-4094","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierr20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}